Financial Consulate’s Syndax Pharmaceuticals SNDX Stock Holding History

Financial Consulate’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$351	Buy	+15	New	+$326	﹤0.01%	1324

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Financial Consulate's SNDX Position: Q1 2026 in Review

Financial Consulate opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 15 shares worth $351. The stake represents ﹤0.01% of the portfolio and ranks #1324 among its holdings.

246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Financial Consulate held 15 shares of Syndax Pharmaceuticals worth $351 as of Q1 2026.
Syndax Pharmaceuticals was a new Financial Consulate position in Q1 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1324 holding.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.